One-centre Safety and Pharmacokinetics Phase I Study of Inhaled Esketamine in Healthy Volunteers With Two Single Ascending Dose and One Double-blind Multiple Ascending Dose Parts
Phase of Trial: Phase I
Latest Information Update: 01 Nov 2018
Price : $35 *
At a glance
- Drugs Esketamine (Primary)
- Indications Major depressive disorder
- Focus Pharmacokinetics
- Sponsors Celon Pharma
- 09 Oct 2018 Results of open label, two-part, single-ascending dose study (n= 30; part A and B), presented at the 31st Annual Congress of the European College of Neuropsychopharmacology.
- 11 Jul 2018 Status changed from recruiting to completed.
- 31 Jan 2018 New trial record